Is the healthcare sector a hedge against an AI stock downturn?
For much of the past several years, healthcare stocks have occupied an uncomfortable position in the equity market. Drug-pricing politics, rising medical costs and uncertainty about future earnings kept valuations subdued, while investors directed capital toward technology companies expected to benefit from artificial intelligence. Healthcare was often treated as a source of stability rather than growth.
That relationship is changing. Healthcare stocks have rallied as investors question the durability of the AI investment boom, and the sector’s traditional valuation discount to the broader market has disappeared. The shift is important not simply because healthcare is performing well, but because it may signal a broader reassessment of the risks embedded in technology valuations.
For wealth advisors, the central question is not whether healthcare has become expensive or AI stocks have peaked. It is whether investors are beginning to demand a different balance between growth, earnings visibility and valuation—and what that means for portfolio construction if the market’s leadership changes.
Healthcare’s Repricing Signals a Change in Market Priorities
Healthcare spent much of the past few years in the market’s bargain bin. Investors worried about government intervention in prescription drug pricing under both the Biden and Trump administrations, while rising medical costs created additional uncertainty for health insurers. Meanwhile, enthusiasm for AI-related businesses drew capital toward technology stocks, leaving healthcare relatively neglected.
A year ago, healthcare traded at approximately a 25% discount to the S&P 500. That gap has since closed. According to FactSet data, the Health Care Select Sector SPDR ETF (XLV) recently traded at 19.3 times forward earnings, slightly above the S&P 500.
The change reflects more than improving sentiment toward pharmaceutical companies, medical-device manufacturers and healthcare providers. It also reflects growing questions about the assumptions supporting technology valuations.
Over the past several days, concerns that rising interest rates could constrain AI spending have encouraged investors to move toward defensive stocks. Healthcare has been among the S&P 500’s strongest-performing sectors. XLV gained more than 2% on Monday, led by advances of 6.7% in Moderna and 4.9% in Bristol Myers Squibb.
These moves do not establish that a durable rotation is underway. Sector rallies can reflect short covering, changing expectations for interest rates or temporary portfolio adjustments. Nevertheless, the disappearance of healthcare’s valuation discount suggests investors are increasingly willing to pay for earnings they perceive as more resilient.
For advisors, this is a useful distinction: A change in market leadership can begin before the market has definitively identified a new economic growth engine.
Why Healthcare Could Benefit From AI Anxiety
Healthcare’s appeal becomes clearer when viewed through three variables: confidence in medical innovation, concern about the durability of profits in other industries, and the severity of policy headwinds.
The current environment has improved healthcare’s relative position on all three dimensions.
First, medical innovation remains a source of potential growth. Pharmaceutical research, biotechnology, medical devices and new treatment approaches can create substantial commercial opportunities independent of the spending cycle for AI infrastructure. Successful drug development can generate years of revenue, although clinical failures, patent expirations and regulatory decisions make those earnings far from certain.
Second, the market is beginning to scrutinize the returns on AI investment. Technology companies are committing substantial capital to data centers, chips, computing infrastructure and electricity. The investment thesis depends on AI generating enough revenue, productivity gains or strategic advantage to justify that spending.
That is a demanding requirement. Even if AI adoption continues, investors may discover that the financial benefits arrive more slowly than expected, accrue disproportionately to a small number of companies, or fail to justify current valuations.
Healthcare offers a different earnings profile. Demand for many medical services and treatments is relatively insensitive to short-term economic fluctuations. Established pharmaceutical companies can generate substantial cash flow, while medical-device businesses may benefit from aging populations and ongoing treatment needs.
The sector is not immune to economic pressures, and its constituent businesses have very different risk profiles. Still, its earnings drivers are sufficiently distinct from those of AI infrastructure companies to make it a potential source of diversification.
Third, policy uncertainty remains significant but is no longer necessarily an insurmountable obstacle to investment. Investors may become more comfortable underwriting healthcare earnings when pricing rules, reimbursement arrangements and regulatory expectations become easier to assess. That does not mean political risks have disappeared; rather, markets can adapt to risks they believe are increasingly reflected in valuations.
The result is a sector that may look attractive precisely when investors become less confident that technology companies can sustain their current profit expectations.
What History Says About the Next Phase
Healthcare has periodically commanded a valuation premium to the broader market. Notable periods included 2003 to 2007 and 2013 to 2015. A shorter episode emerged in late 2022, when inflation surged, the Federal Reserve raised interest rates and the S&P 500 sold off.
These precedents suggest that healthcare’s relative performance can improve when investors prioritize earnings resilience, medical innovation or protection against uncertainty elsewhere.
The more consequential historical parallel involves the aftermath of investment booms.
When a dominant investment theme loses momentum, the consequences can extend beyond an immediate market correction. Capital can migrate toward companies with stronger balance sheets, more dependable cash generation and valuations that require less optimistic assumptions. That process can create opportunities for sectors that were previously overlooked.
If the AI boom eventually ends in a significant valuation contraction, healthcare could outperform for an extended period. Such outperformance would not necessarily require healthcare stocks to rise in absolute terms. They could simply decline less than technology stocks during a broad selloff or deliver more consistent earnings while investors reassess growth expectations.
However, advisors should avoid treating history as a timetable. Previous healthcare leadership periods do not establish when the next one will end, and the sector’s present valuation premium means some of the opportunity may already be reflected in prices.
The relevant lesson is not that healthcare must outperform after an AI correction. It is that market leadership can persist longer than expected, then change quickly when investors revise their assumptions about future profits.
What Healthcare’s Rise Means for AI Stocks
Healthcare’s strength creates three potential implications for technology investors.
1. AI valuations may face greater scrutiny.
The first implication is a higher hurdle for AI-related earnings. When investors are enthusiastic about a new technology, they often accept elevated valuations because they expect rapid revenue growth and expanding margins. As uncertainty increases, the market becomes less forgiving of companies whose valuations depend on years of future earnings growth.
Higher interest rates can intensify that pressure by reducing the present value of distant cash flows. They can also raise financing costs and make capital-intensive infrastructure investments less attractive.
A rotation into healthcare does not prove that AI stocks are in a bubble. Nor does it establish that their earnings prospects are deteriorating. It does, however, suggest that investors may be reassessing how much they are willing to pay for uncertain future growth.
2. Technology leadership could narrow before it reverses.
A change in market leadership need not begin with a dramatic collapse in the largest technology companies. It may first appear as weaker performance among highly valued companies, greater dispersion between AI winners and losers, or stronger returns from businesses with less demanding valuations.
That distinction matters because broad market indexes can conceal significant changes underneath the surface. A handful of mega-cap technology companies can continue supporting the S&P 500 even as other stocks struggle.
Advisors should therefore monitor market breadth, earnings revisions, capital expenditure commitments and evidence that AI spending is translating into measurable returns. A sector rotation is more informative when supported by deteriorating fundamentals in the previous leaders than when it reflects only short-term changes in investor positioning.
3. The AI opportunity may survive a valuation reset.
The long-term adoption of AI and the short-term performance of AI stocks are separate questions. A technology can transform industries while many investors lose money buying companies at excessive valuations.
Healthcare itself illustrates this distinction. Medical innovation can create substantial value, but that does not guarantee that every biotechnology or pharmaceutical stock will succeed. Clinical outcomes, pricing pressure and competition ultimately determine which companies capture the benefits.
The same discipline applies to AI. Advisors should distinguish between companies with durable competitive advantages and defensible cash flows and those whose valuations depend heavily on continued investor enthusiasm.
If AI spending slows, some businesses may prove vulnerable. Others may continue to benefit from productivity gains, infrastructure demand or the integration of AI into existing products. A selective approach is more defensible than treating the entire sector as either indispensable or overvalued.
How Advisors Should Position Client Portfolios
The appropriate response is not to abandon technology and chase healthcare after a strong rally. That would replace one form of concentration risk with another.
Instead, advisors should use healthcare’s resurgence as an opportunity to reassess the assumptions embedded in client portfolios.
Start with concentration. Clients whose equity exposure is heavily dependent on a small group of technology companies may have more correlated risk than their account statements suggest. Diversification across sectors, business models and earnings drivers can help reduce that exposure.
Next, examine valuation sensitivity. Companies whose prices depend on distant cash flows are generally more vulnerable to changes in discount rates and growth expectations than businesses generating substantial cash today. This does not make the former inherently inferior investments, but it changes how much valuation risk a portfolio can reasonably absorb.
Healthcare allocations also deserve a more discriminating review. The sector includes profitable pharmaceutical companies, speculative biotechnology businesses, medical-device manufacturers, healthcare providers and insurers. Their economic sensitivities and risks differ substantially. A broad sector ETF provides diversification within healthcare, but it does not eliminate exposure to drug-pricing policy, reimbursement pressures or valuation risk.
Finally, stress-test portfolios against several scenarios: continued AI-led market gains, a prolonged period of narrow technology leadership, and a sharp correction in AI-related valuations accompanied by weaker economic growth. The objective is not to predict which scenario will occur. It is to identify whether clients can tolerate each outcome without abandoning their long-term plans.
For clients approaching retirement or funding near-term spending needs, that exercise should include liquidity requirements and the consequences of selling volatile assets during a downturn. For clients with long investment horizons, the emphasis may be on maintaining disciplined exposure to long-term growth while avoiding excessive dependence on a single investment theme.
The Advisor’s Message: Diversification, Not Rotation for Its Own Sake
Healthcare’s move from a deep valuation discount to a modest premium is a meaningful change in market behavior. It suggests investors are becoming more selective about where they expect reliable profits and how much uncertainty they are willing to tolerate.
That shift could persist even if AI spending continues to grow. It could also reverse if technology companies demonstrate that their investments are producing stronger-than-expected returns, or if healthcare faces renewed pricing and regulatory pressure.
Advisors should resist presenting the development as a simple choice between healthcare and AI. The more useful client conversation concerns the relationship between price, earnings durability and portfolio resilience.
AI may remain one of the defining investment themes of the coming decade. But its importance to the economy does not guarantee uninterrupted stock-market leadership. Similarly, healthcare’s essential role in the economy does not guarantee attractive returns at every valuation.
The opportunity is to build portfolios that can participate in technological progress without depending on a single outcome. Healthcare’s resurgence is a reminder that markets periodically reward businesses with different sources of growth, more defensive earnings and less exposure to the investment cycle driving the headlines.
If the AI boom eventually falters, healthcare could be among the beneficiaries. Advisors do not need to predict that turning point to prepare for it. They need to recognize the risks already present in client portfolios, maintain valuation discipline and ensure diversification is designed to withstand a change in market leadership rather than simply reflect the last one.

